ストックスクリーナーアプリを入手
43.62
0.71%
-0.31
アフターアワーズ：
43.81
0.19
+0.44%
前日終値:
$43.93
開ける：
$44.1
24時間の取引高:
5.64M
Relative Volume:
1.01
時価総額：
$7.83B
収益：
$1.36B
当期純損益:
$-302.91M
株価収益率:
-25.39
EPS:
-1.7182
ネットキャッシュフロー:
$-219.93M
1週間 パフォーマンス:
-9.99%
1か月 パフォーマンス:
-21.93%
6か月 パフォーマンス:
-34.67%
1年 パフォーマンス:
-33.39%
1日の値動き範囲:
$43.13
$45.72
1週間の範囲:
$43.13
$48.13
52週間の値動き範囲:
$41.73
$104.32
Tempus Ai Inc Stock (TEM) Company Profile
Compare TEM vs VEEV, BTSG, HQY, HNGE
| 株式 | 価格 | 時価総額 | 収益 | 当期純利益 | 現金流量 | EPS |
|---|---|---|---|---|---|---|
TEM
Tempus Ai Inc
|
43.62 | 7.89B | 1.36B | -302.91M | -219.93M | -1.7182 |
VEEV
Veeva Systems Inc
|
163.85 | 25.93B | 3.20B | 908.91M | 1.39B | 5.4168 |
BTSG
Brightspring Health Services Inc
|
56.18 | 11.23B | 13.65B | 169.86M | 412.12M | 1.0758 |
HQY
Healthequity Inc
|
83.04 | 6.89B | 1.31B | 215.20M | 408.32M | 2.4627 |
HNGE
Hinge Health Inc
|
54.71 | 4.22B | 646.34M | -512.40M | 202.76M | -6.6871 |
Tempus Ai Inc Stock (TEM) Upgrades & Downgrades
| 日付 | アクション | アナリスト | 評価の変更 |
|---|---|---|---|
| 2026-04-13 | 開始されました | Jefferies | Underperform |
| 2026-04-13 | アップグレード | TD Cowen | Hold → Buy |
| 2026-02-19 | 開始されました | Mizuho | Outperform |
| 2026-02-17 | 開始されました | Robert W. Baird | Outperform |
| 2025-12-02 | 再開されました | Morgan Stanley | Overweight |
| 2025-10-21 | ダウングレード | TD Cowen | Buy → Hold |
| 2025-10-20 | 開始されました | Canaccord Genuity | Buy |
| 2025-09-02 | 開始されました | H.C. Wainwright | Buy |
| 2025-04-21 | 開始されました | BTIG Research | Buy |
| 2025-02-25 | ダウングレード | JP Morgan | Overweight → Neutral |
| 2025-02-12 | ダウングレード | William Blair | Outperform → Mkt Perform |
| 2025-02-05 | 再開されました | TD Cowen | Buy |
| 2024-12-13 | 開始されました | Wolfe Research | Outperform |
| 2024-12-09 | 開始されました | Guggenheim | Buy |
| 2024-11-11 | ダウングレード | Stifel | Buy → Hold |
| 2024-10-02 | ダウングレード | BofA Securities | Buy → Neutral |
| 2024-08-12 | 開始されました | Piper Sandler | Neutral |
| 2024-07-09 | 開始されました | BofA Securities | Buy |
| 2024-07-09 | 開始されました | JP Morgan | Overweight |
| 2024-07-09 | 開始されました | Longbow | Buy |
| 2024-07-09 | 開始されました | Loop Capital | Buy |
| 2024-07-09 | 開始されました | Morgan Stanley | Overweight |
| 2024-07-09 | 開始されました | Needham | Buy |
| 2024-07-09 | 開始されました | Stifel | Buy |
| 2024-07-09 | 開始されました | TD Cowen | Buy |
| 2024-07-09 | 開始されました | William Blair | Outperform |
すべてを表示
Tempus Ai Inc (TEM) 最新ニュース
Assessing Tempus AI (TEM) Valuation After Recent Share Price Weakness - Yahoo Finance
Tempus AI, Bristol Myers Squibb Expand AI-Driven Clinical Trial Efforts - Yahoo Finance
Tempus AI And BMS Deepen AI Drug Development Ties As Losses Persist - Yahoo Finance
How Beaten-Down Tempus AI Stock Offers a Lottery Ticket for Traders Here - Barchart.com
7 Healthcare AI Stocks Under $50 With Huge Upside Potential - 24/7 Wall St.
Cathie Wood’s weekly update: buys Cerebras, Tempus AI, sells AMD and TSM (ARKK:BATS) - Seeking Alpha
Tempus AI, Inc. Class A Common Stock (TEM) Live Share Price, Invest From India - INDmoney
Tempus AI stock jumps, ALERT trial results boost EHR automation buzz - MSN
Tempus AI stock gains following the ALERT trial result announcement - MSN
Cathie Wood buys $14.9 million of Tempus AI stock - MSN
Tempus AI Inc (TEM) Stock Price, Quote, News & History - Benzinga
Tempus AI (TEM) executive Fukushima Ryan makes bona fide stock gifts under lock-up - Stock Titan
HIMS Stock Dips 14.3% Since Q1 Earnings: Should You Still Hold or Sell? - TradingView
Tempus AI, Inc. (NASDAQ:TEM) Receives Consensus Recommendation of "Moderate Buy" from Analysts - MarketBeat
Tempus AI shares gain after expanded partnership with Gilead - MSN
Alzheimer’s Blood-Based Biomarker Testing Integrated into Clinical Workflows - Clinical Lab Products
Tempus Expands Strategic Collaboration with Bristol Myers Squibb to Enhance the Probability of Success Across Clinical Development Programs In Oncology and Neuroscience - Quantisnow
Tempus AI Stock (TEM) Opinions on Bristol Myers Squibb Partnership Expansion - Quiver Quantitative
Here’s Why Aristotle Core Equity Fund Bets on Tempus AI (TEM), a Healthcare Technology Company - Insider Monkey
AI aims to reshape Bristol Myers’ cancer and Alzheimer’s drug trials - Stock Titan
Baillie Gifford Reduces Stake in Tempus AI Inc: A Strategic Port - GuruFocus
Tempus AI Announces $350M Convertible Senior Notes Offering to Repay Debt and Enhance Financial Flexibility - Minichart
Tempus AI Completes Convertible Notes Offering, Retires Secured Debt - TipRanks
Tempus AI Prices $460 Million 0% Convertible Notes Due 2032, Retires Senior Credit Facility - TradingView
AI In Medical Imaging Market Expected to Witness Rapid Expansion - openPR.com
TEM Stock Price, Quote & Chart | TEMPUS AI INC-CL A (NASDAQ:TEM) - ChartMill
Tempus AI (NASDAQ: TEM) prices $460M 0% 2032 convertible notes and repays debt - Stock Titan
symbol__ Stock Quote Price and Forecast - CNN
Piper Sandler Maintains Tempus AI(TEM.US) With Hold Rating, Maintains Target Price $58 - Moomoo
Ark Invest Again Sells AMD, This Time As Stock Hits 52-Week High While Snapping Up Tempus AI And Circle - Benzinga
Cathie Wood’s ARK sells AMD stock, buys Kratos and Tempus AI - Investing.com
Tempus AI prices upsized $400M offering - MSN
Artificial Intelligence Stocks Worth WatchingMay 11th - MarketBeat
How Lucent and Tempus Are Using AI to Spot Alzheimer’s Earlier - HIT Consultant
H.C. Wainwright cuts Tempus AI stock price target to $64 on wider losses By Investing.com - Investing.com Australia
H.C. Wainwright cuts Tempus AI stock price target to $64 on wider losses - Investing.com UK
H.C. Wainwright Maintains Tempus AI(TEM.US) With Buy Rating, Cuts Target Price to $64 - Moomoo
Digital tool that flags high-risk patients wins global health tech award - Stock Titan
Tempus AI, Inc. (TEM) Stock Analysis: Exploring The 38.92% Potential Upside For Investors - DirectorsTalk Interviews
Cathie Wood Dumps Another $3 Million In AMD Stock As Ark Invest Trims For Third Day Running, This Is the AI Stock She Is Buying Instead - Yahoo Finance
Tempus AI (TEM) Valuation Check As Q1 2026 Growth And New Pharma Collaborations Refocus Attention - simplywall.st
Tempus AI Raises US$400m As Alzheimer’s Collaboration Broadens Diagnostic Reach - Sahm
Lucent Diagnostics and Tempus AI partner to expand access to Alzheimer’s blood biomarker testing - SelectScience
Top Artificial Intelligence Stocks To ResearchMay 10th - MarketBeat
Is Tempus AI (TEM) The Best AI Healthcare Stock to Buy? - Insider Monkey
Tempus AI targets $1.59B-$1.6B revenue and about $65M adjusted EBITDA in 2026, backed by Merck collaboration - MSN
Tempus AI plans $350M convertible notes offering - MSN
BTIG Maintains Tempus AI (TEM) Buy Recommendation - MSN
Tempus AI Expands Beyond Oncology With New Alzheimer’s Blood Test Alliance - Yahoo Finance
Tempus AI (TEM) reports Q1 loss, beats revenue estimates - MSN
Tempus Ai Inc (TEM) 財務データ
収益
当期純利益
現金流量
EPS
1.06%
2.97%
大文字化:
|
ボリューム (24 時間):